Targeting JAK-STAT signal transduction in IBD

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Targeting JAK-STAT signal transduction in IBD. / Soendergaard, Christoffer; Bergenheim, Fredrik Holmberg; Bjerrum, Jakob Tveiten; Nielsen, Ole Haagen.

I: Pharmacology & Therapeutics, Bind 192, 2018, s. 100-111.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Soendergaard, C, Bergenheim, FH, Bjerrum, JT & Nielsen, OH 2018, 'Targeting JAK-STAT signal transduction in IBD', Pharmacology & Therapeutics, bind 192, s. 100-111. https://doi.org/10.1016/j.pharmthera.2018.07.003

APA

Soendergaard, C., Bergenheim, F. H., Bjerrum, J. T., & Nielsen, O. H. (2018). Targeting JAK-STAT signal transduction in IBD. Pharmacology & Therapeutics, 192, 100-111. https://doi.org/10.1016/j.pharmthera.2018.07.003

Vancouver

Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacology & Therapeutics. 2018;192:100-111. https://doi.org/10.1016/j.pharmthera.2018.07.003

Author

Soendergaard, Christoffer ; Bergenheim, Fredrik Holmberg ; Bjerrum, Jakob Tveiten ; Nielsen, Ole Haagen. / Targeting JAK-STAT signal transduction in IBD. I: Pharmacology & Therapeutics. 2018 ; Bind 192. s. 100-111.

Bibtex

@article{a93a4ab66d1b4a099755af50aa85a3bd,

title = "Targeting JAK-STAT signal transduction in IBD",

abstract = "An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.",

author = "Christoffer Soendergaard and Bergenheim, {Fredrik Holmberg} and Bjerrum, {Jakob Tveiten} and Nielsen, {Ole Haagen}",

year = "2018",

doi = "10.1016/j.pharmthera.2018.07.003",

language = "English",

volume = "192",

pages = "100--111",

journal = "Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and",

issn = "0163-7258",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Targeting JAK-STAT signal transduction in IBD

AU - Soendergaard, Christoffer

AU - Bergenheim, Fredrik Holmberg

AU - Bjerrum, Jakob Tveiten

AU - Nielsen, Ole Haagen

PY - 2018

Y1 - 2018

N2 - An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

AB - An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

U2 - 10.1016/j.pharmthera.2018.07.003

DO - 10.1016/j.pharmthera.2018.07.003

M3 - Journal article

C2 - 30048708

VL - 192

SP - 100

EP - 111

JO - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and

JF - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and

SN - 0163-7258

ER -

ID: 216566646